Ekf Diagnostics Holding PLC (LON:EKF)‘s stock had its “buy” rating reaffirmed by stock analysts at Panmure Gordon in a research note issued on Friday. They currently have a GBX 17.50 ($0.23) target price on the stock. Panmure Gordon’s target price indicates a potential upside of 19.66% from the stock’s previous close.
EKF has been the topic of a number of other research reports. N+1 Singer raised their price target on Ekf Diagnostics Holding PLC from GBX 18 ($0.23) to GBX 19 ($0.25) and gave the stock a “buy” rating in a report on Monday, September 12th. FinnCap reissued an “under review” rating on shares of Ekf Diagnostics Holding PLC in a report on Tuesday, August 30th.
Shares of Ekf Diagnostics Holding PLC (LON:EKF) opened at 17.1875 on Friday. The stock’s market capitalization is GBX 73.70 million. The stock has a 50 day moving average price of GBX 14.89 and a 200-day moving average price of GBX 13.22. Ekf Diagnostics Holding PLC has a 52-week low of GBX 7.00 and a 52-week high of GBX 23.45.
In other Ekf Diagnostics Holding PLC news, insider Mills,Christopher H. B acquired 9,000,000 shares of the stock in a transaction on Friday, July 15th. The shares were bought at an average price of GBX 15 ($0.20) per share, with a total value of £1,350,000 ($1,762,172.04).
Ekf Diagnostics Holding PLC Company Profile
EKF Diagnostics Holdings Plc is focused on the In-Vitro Diagnostic device (IVD) market place. The Company is engaged in the designing, development, manufacture and selling of diagnostic instruments, reagents and certain ancillary products. This activity takes place across various geographical locations which include the United States America, Germany, Poland, Russia, United Kingdom and Ireland.
Receive News & Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related companies with MarketBeat.com's FREE daily email newsletter.